Introduction {#s1}
============

Intracerebral hemorrhage (ICH) is the most lethal stroke subtype with a mortality of about 40% at 1 month ([@B1]). Hematoma expansion (HE) occurs within a few hours after the initial bleeding ([@B2]), and it has been ascertained as a strong predictor of early neurological deterioration and poor long-term functional outcomes ([@B3]--[@B5]). Therefore, identifying ICH patients at high risk of early HE and taking hemostasis treatment are of great significance.

Although the chronic inflammation mediates ICH-induced secondary brain injury ([@B6]), acute inflammation reaction is beneficial for early benign transformation of the hematoma ([@B7], [@B8]). Peripheral white blood cells (WBC), is often used as a marker for central nervous system (CNS) inflammation and its role in the pathophysiology of acute ICH has been well-recognized ([@B9]--[@B11]). Preclinical studies have found that leukocytes infiltrate around the hematoma within hours following ICH, and neutrophils are the earliest inflammatory cells to invade the CNS ([@B11], [@B12]). Interleukin-27/lactoferrin-mediated neutrophil polarization can enhance hematoma clearance and improve neurological function in an animal model of ICH ([@B7]). In clinical studies, the relevance of leukocyte counts to poor ICH prognosis has received increasing attention, but no consensus is reached ([@B13]--[@B16]). Early hematoma growth, as a potential mechanism of this association, was also found in relation to admission WBC count ([@B8]). However, results with respect to the individual contributions of leukocyte subtypes to HE were inconsistent between literatures. Result from a study with large ICH population showed that the risk of HE was directly associated with monocyte count when HE was defined as a volume increase \>6 mL or 30% ([@B8]). In another study defining HE as any degree of growth, investigators found no association between admission monocyte count and HE ([@B17]).

We hypothesized that growth definition might affect the stability of this association. In this study, we aimed to determine the relationship between absolute and differential leukocyte counts and HE across various growth definitions by using propensity score-matching method. Clarifying the connection of HE with leukocyte counts may provide reasonable evidence for linking inflammation to clinical prognosis in patients with acute ICH and develop potential therapeutic strategies on the HE.

Materials and Methods {#s2}
=====================

Study Participants
------------------

We retrospectively evaluated spontaneous ICH patients admitted to our Neurological Emergency Room from September 2013 to August 2018. In total, 2,546 cases who underwent baseline computed tomography (CT) scan within 6 h and follow-up CT scan within 72 h of symptom onset were initially enrolled. Patients who met the following conditions were subsequently excluded from this study: (1) traumatic intracerebral hemorrhage or hemorrhagic transformation of a brain infarction (*n* = 746), (2) tumor, aneurysm or arteriovenous malformation presumed to be the potential cause of the bleeding (*n* = 95), (3) primary intraventricular hemorrhage or multiple cerebral hemorrhage (*n* = 47), (4) presence of encephalitis, pneumonia, or parasitic infection during the past week (*n* = 41), (5) surgical evacuation performed before the follow-up CT (*n* = 506), (6) usage of anticoagulants or antiplatelet drugs before intracerebral hemorrhage (*n* = 30), and (7) lack of complete blood count data on admission (*n* = 15). Our study was approved by the Medical Ethics Committee of The First Affiliated Hospital of Wenzhou Medical University. Written informed consent for each participant was waived owing to the retrospective nature of the study.

Image Acquisition and Analysis
------------------------------

The baseline and follow-up CT scans were performed using a standard clinical protocol with an axial technique of 5-mm section thickness, tube current of 80 mA, and tube voltage of 120 kV(p). All CT images were acquired from the picture archiving and communication system (PACS) and saved as DICOM format for further evaluation. Two experienced radiologists who were blinded to clinical and laboratory data independently analyzed the images. Volumetric calculation of hematoma was completed through 3-dimensional reconstruction of the regions of interest obtained by manually depicting the lesions circumference in multiple successive layers. The volume extended to the ventricles did not be calculated. When the hematoma boundary at a certain layer was unclear, it was settled by joint discussion of the 2 readers. To assess the reliability of volume measurements between the 2 observers, we randomly selected 100 patients from the entire sample and analyzed the consistency by using the intra-group correlation coefficient (ICC). Hematoma location was also evaluated and divided into lobe, deep, and infratentorial. Both imaging assessments and volume measurements were conducted at the post-processing station (GE Healthcare Advantage Workstation; Version 4.6). According to the most commonly used definitions of HE in previous studies, we categorized HE as \>33% growth, \>6 mL growth, \>12.5 mL growth, and their combinations (\>6 mL or 33%, and \>12.5 mL or 33%).

Clinical and Laboratory Variables
---------------------------------

Demographics (sex and age) and clinical data (glasgow coma scale score, history of hypertension, diabetes mellitus, smoking, alcohol consumption, coronary heart disease, cerebral infarction, and cerebral hemorrhage) were reviewed from the inpatient medical records. The time from symptom onset to baseline CT was also calculated. We collected laboratory parameters from the emergency medical record system, including glucose level, platelet count, international normalized ratio, total WBC count, and differential leukocyte counts (neutrophil count, monocyte count, lymphocyte count, and eosinophil count). Routine blood sampling for each participant was completed within 1 h after admission, but prior to the baseline CT imaging. Before testing, venous blood sample was placed in a 2.0 mL of disposable collection tube, which contained EDTA-K2 for the purpose of anticoagulation. Complete blood count was measured by an automatic XE-2100 hematology analyzer (Sysmex Corporation, Kobe, Japan).

Statistical Analysis
--------------------

All statistical analyses were performed using IBM SPSS Statistics (Version 22.0). First, the entire cohort were dichotomized according to the 2 combined definitions of HE. The discrete variables were expressed as frequency (percentage), and the continuous variables were presented as mean ± standard deviation (SD) or median \[interquartile range (IQR)\]. The demographic, clinical, and radiological characteristics were compared between patients with HE and those without. Statistical significance for the difference between the 2 groups was examined by χ^2^ test or the Fisher exact test for categorical variables, and by student *t*-test or Mann-Whitney *U*-test for continuous variables. Multivariable logistic regression models were performed to initially evaluate the associations of ICH expansion risk with absolute and differential leukocyte counts. The variables with *p* \< 0.05 from both univariate analyses were forced into the multivariate model.

Subsequently, a propensity score-matching analysis was used to balance the distribution of covariates between patients who experienced HE and those without. A propensity score was calculated for each patient using logistic regression analysis, and the variables with *p* \< 0.2 in the above univariate analyses were introduced into the propensity model. The included variables are as follows: sex, hypertension, drinking, history of cerebral hemorrhage, glasgow coma scale score, platelet count, intraventricular hemorrhage, baseline ICH volume, and time from onset to initial CT. Patients with HE were then matched 1:1 without replacement to patients who did not experience HE using the nearest neighbor approach with a 0.02 caliper width. Multivariate logistic regression model was further performed to assess the relationship of leukocyte counts with HE across the various HE definitions, adjusting for predictors of HE that were previously validated in the randomized clinical trial and multicenter prospective study ([@B18]--[@B20]). Finally, in the entire cohort, we performed a receiver operating characteristic analysis to assess the discrimination ability of different leukocyte counts components for predicting HE. A value of *p* \< 0.05 (2 sided) was considered statistically significant.

Results {#s3}
=======

A total of 1,066 patients met the inclusion criteria and were analyzed. With the 5 types of growth definition, HE occurred in 200 (18.8%), 116 (10.9%), 174 (16.3%), 225 (21.1%), 182 (17.1%) of all patients, respectively. There were 699 men and 367 women, and the mean age was 61.5 ± 12.6 years (range 25--95 years). The ICC in volumetric measurement between the 2 observers was 0.96 (95% confidence interval \[CI\], 0.95--0.98), indicating an excellent consistency.

In the entire cohort, univariate analyses based on the 2 combined HE definitions showed that the clinical and imaging characteristics presented similar trend between patients with HE and non-HE ([Tables 1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}). Patients with HE had a higher median baseline hematoma volume than those without (24.4 \[13.9--35.4\] vs. 16.2 \[9.1--27.0\] mL; 21.3 \[12.6--30.6\] vs. 17.1 \[9.4--28.3\] mL; *p* \< 0.001 and *p* = 0.012, respectively), and they had a shorter time from symptom onset to initial CT (both *p* \< 0.001). Patients who experienced HE also had a lower admission glasgow coma scale score compared to patients without HE (both *p* \< 0.001). History of cerebral hemorrhage was more frequently observed among individuals with HE (*p* = 0.015; *p* = 0.003), while hypertension was less commonly in those individuals (*p* = 0.001; *p* = 0.008). Besides, patients with HE were more likely to be male than those with non-HE (76.4 vs. 62.7%; 76.9 vs. 63.2%; both *p* \< 0.001). Multivariable analyses ([Table 3](#T3){ref-type="table"}) showed that in addition to using the definition of \>12.5 mL growth, both WBC and neutrophil count were independently associated with reduced risk of HE (odds ratio \[OR\] for 10^3^ cells increase; OR, 0.93--0.95 and OR, 0.92--0.96, respectively; all *p* \< 0.05) after adjusting for risk factors selected in the univariate analyses. However, monocyte count was correlated with increased risk of HE only when using the growth definition of \>12.5 mL (OR, 1.98; *p* = 0.009). There was no significant association between lymphocyte count and HE (all *p* \> 0.05). Regardless of the growth definition, the risk of HE was directly associated with eosinophil count (OR, 3.64--6.71; all *p* \< 0.05).

###### 

Comparison of baseline characteristics between HE (\>6 mL or 33%) and non-HE groups in the original cohort.

  **Characteristics**                 **Non-HE (*n* = 841)**   **HE (*n* = 225)**   ***P-*value**
  ----------------------------------- ------------------------ -------------------- ----------------------------------------
  Age                                 61.6 ± 12.7              60.9 ± 12.5          0.468
  Male sex                            527 (62.7)               172 (76.4)           \<0.001[\*](#TN1){ref-type="table-fn"}
  Hypertension                        680 (80.9)               160 (71.1)           0.001[\*](#TN1){ref-type="table-fn"}
  Diabetes mellitus                   94 (11.2)                25 (11.1)            0.978
  Current or previous smoking         235 (27.9)               66 (29.3)            0.681
  Current or previous drinking        232 (27.6)               69 (30.7)            0.362
  History of coronary heart disease   10 (1.2)                 3 (1.3)              0.861
  History of cerebral infarction      32 (3.8)                 7 (3.1)              0.622
  History of cerebral hemorrhage      29 (3.5)                 16 (7.1)             0.015[\*](#TN1){ref-type="table-fn"}
  Glasgow coma scale score            14 (11--15)              11 (8--15)           \<0.001[\*](#TN1){ref-type="table-fn"}
  International normalized ratio      0.99 (0.94--1.04)        0.99 (0.94--1.05)    0.209
  Glucose level, mmol/L               7.0 (6.0--8.6)           7.0 (6.0--8.2)       0.631
  Platelet count, 10^3^ cells/μL      204 (168--244)           199 (153--238)       0.06
  Time from onset to initial CT, h    3.0 (2.0--4.5)           2.5 (1.5--3.5)       \<0.001[\*](#TN1){ref-type="table-fn"}
  **Location of ICH**                                                               **0.242**
  Lobe                                76 (9.0)                 16 (7.1)             
  Deep                                707 (84.1)               199 (88.4)           
  Infratentorial                      58 (6.9)                 10 (4.4)             
  Baseline ICH volume, mL             16.2 (9.1--27.0)         24.4 (13.9--35.4)    \<0.001[\*](#TN1){ref-type="table-fn"}
  Intraventricular extension          291 (34.6)               93 (41.3)            0.062

*Continuous variables are presented as mean ± SD or median (IQR); Categorical variables are presented as n (%)*.

*ICH, intracerebral hemorrhage; HE, hematoma expansion; CT, computed tomography; SD, standard deviation; IQR, interquartile range*.

*Significant at P \< 0.05*.

###### 

Comparison of baseline characteristics between HE (\>12.5 mL or 33%) and non-HE groups in the original cohort.

  **Characteristics**                 **Non-HE (*n* = 884)**   **HE (*n* = 182)**   ***P-*value**
  ----------------------------------- ------------------------ -------------------- ----------------------------------------
  Age                                 61.6 ± 12.6              60.7 ± 12.9          0.354
  Male sex                            559 (63.2)               140 (76.9)           \<0.001[\*](#TN2){ref-type="table-fn"}
  Hypertension                        710 (80.3)               130 (71.4)           0.008[\*](#TN2){ref-type="table-fn"}
  Diabetes mellitus                   98 (11.1)                21 (11.5)            0.897
  Current or previous smoking         252 (28.5)               49 (26.9)            0.718
  Current or previous drinking        242 (27.4)               59 (32.4)            0.169
  History of coronary heart disease   12 (1.4)                 1 (0.5)              0.366
  History of cerebral infarction      33 (3.7)                 6 (3.3)              0.775
  History of cerebral hemorrhage      30 (3.4)                 15 (8.3)             0.003[\*](#TN2){ref-type="table-fn"}
  Glasgow coma scale score            14 (10--15)              12 (8--15)           \<0.001[\*](#TN2){ref-type="table-fn"}
  International normalized ratio      0.99 (0.94--1.04)        0.99 (0.94--1.05)    0.385
  Glucose level, mmol/L               7.0 (6.1--8.6)           6.9 (6.0--8.2)       0.275
  Platelet count, 10^3^ cells/μL      203 (168--243)           201 (149--239)       0.134
  Time from onset to initial CT, h    3.0 (2.0--4.5)           2.5 (1.5--3.5)       \<0.001[\*](#TN2){ref-type="table-fn"}
  **Location of ICH**                                                               **0.243**
  Lobe                                81 (9.2)                 11 (6.0)             
  Deep                                744 (84.2)               162 (89.0)           
  Infratentorial                      59 (6.7)                 9 (4.9)              
  Baseline ICH volume, mL             17.1 (9.4--28.3)         21.3 (12.6--30.6)    0.012[\*](#TN2){ref-type="table-fn"}
  Intraventricular extension          312 (35.3)               72 (39.6)            0.275

*ICH, intracerebral hemorrhage; HE, hematoma expansion; CT, computed tomography; SD, standard deviation; IQR, interquartile range*.

*Significant at P \< 0.05*.

###### 

Multivariate analyses of predicting hematoma expansion in the original cohort.

                                                        **Crude OR (95%CI)**   ***P-*value**   **Adjusted[^**a**^](#TN3){ref-type="table-fn"} OR (95%CI)**   ***P-*value**
  ----------------------------------------------------- ---------------------- --------------- ------------------------------------------------------------- ---------------
  **\>6 mL growth (*****N*** **=** **200)**                                                                                                                  
  WBC count                                             0.96 (0.92--1.01)      0.088           0.94 (0.90--0.99)                                             0.021
  Neutrophil count                                      0.94 (0.90--0.99)      0.008           0.93 (0.89--0.98)                                             0.008
  Monocyte count                                        1.74 (1.10--2.78)      0.019           1.45 (0.89--2.35)                                             0.131
  Lymphocyte count                                      1.27 (1.09--1.49)      0.003           1.09 (0.90--1.31)                                             0.385
  Eosinophil count                                      7.11 (2.30--21.97)     0.001           3.64 (1.04--12.7)                                             0.043
  **\>12.5 mL growth (*****N*** **=** **116)**                                                                                                               
  WBC count                                             0.97 (0.92--1.02)      0.234           0.98 (0.92--1.04)                                             0.495
  Neutrophil count                                      0.94 (0.89--0.99)      0.023           0.96 (0.91--1.02)                                             0.229
  Monocyte count                                        2.09 (1.26--3.48)      0.004           1.98 (1.19--3.30)                                             0.009
  Lymphocyte count                                      1.35 (1.13--1.61)      0.001           1.14 (0.92--1.40)                                             0.233
  Eosinophil count                                      11.39 (3.27--39.66)    \<0.001         5.03 (1.13--22.3)                                             0.034
  **\>33% growth (*****N*** **=** **174)**                                                                                                                   
  WBC count                                             0.92 (0.88--0.97)      0.001           0.94 (0.89--0.99)                                             0.02
  Neutrophil count                                      0.89 (0.85--0.94)      \<0.001         0.96 (0.87--0.97)                                             0.003
  Monocyte count                                        1.79 (1.12--2.88)      0.016           1.62 (0.99--2.64)                                             0.056
  Lymphocyte count                                      1.42 (1.21--1.67)      \<0.001         1.18 (0.99--1.42)                                             0.072
  Eosinophil count                                      19.12 (5.81--62.94)    \<0.001         6.71 (1.73--25.9)                                             0.006
  **\>6 mL or 33% growth (*****N*** **=** **225)**                                                                                                           
  WBC count                                             0.95 (0.91--0.99)      0.008           0.93 (0.89--0.98)                                             0.004
  Neutrophil count                                      0.92 (0.88--0.96)      \<0.001         0.92 (0.87--0.96)                                             \<0.001
  Monocyte count                                        1.73 (1.09--2.75)      0.019           1.44 (0.90--2.30)                                             0.127
  Lymphocyte count                                      1.37 (1.17--1.59)      \<0.001         1.19 (0.99--1.42)                                             0.053
  Eosinophil count                                      10.38 (3.37--32.02)    \<0.001         4.66 (1.28--17.02)                                            0.02
  **\>12.5 mL or 33% growth (*****N*** **=** **182)**                                                                                                        
  WBC count                                             0.93 (0.89--0.98)      0.004           0.95 (0.90--0.99)                                             0.034
  Neutrophil count                                      0.90 (0.86--0.95)      \<0.001         0.93 (0.88--0.98)                                             0.005
  Monocyte count                                        1.80 (1.12--2.89)      0.015           1.61 (0.92--2.61)                                             0.124
  Lymphocyte count                                      1.41 (1.20--1.66)      \<0.001         1.20 (0.92--1.43)                                             0.112
  Eosinophil count                                      17.07 (5.25--55.49)    \<0.001         6.51 (1.71--24.82)                                            0.006

*OR for 10^3^ cells increase. N represents the number of positive hematoma expansion*.

*Adjusted by sex, hypertension, history of cerebral hemorrhage, glasgow coma scale score, time from symptom onset to initial CT, and baseline hematoma volume. WBC, white blood cell; OR, odds ratio; CI, confidence interval; CT, computed tomography*.

Propensity score-matching analyses resulted in 380 (190 pairs), 232 (116 pairs), 326 (163 pairs), 432 (216 pairs), and 358 (179 pairs) patients being matched across the 5 types of HE definition. In the propensity score-matched cohorts, univariate analyses demonstrated that there were no significant difference between HE and non-HE groups regarding the baseline clinical and radiological characteristics (all *p* \> 0.05; [Tables 4](#T4){ref-type="table"}, [5](#T5){ref-type="table"}). The admission absolute and differential leukocyte counts in patients with and without HE were summarized in [Table 6](#T6){ref-type="table"}. As shown in [Table 6](#T6){ref-type="table"}, eosinophil count was significantly associated with HE before and after propensity score matching (all *p* \< 0.05). After adjusting for proven predictors of HE including history of ICH, glasgow coma scale score, time to initial CT, and baseline ICH volume, the results of multivariate regression model were similar to the findings before propensity score-matching analysis ([Table 7](#T7){ref-type="table"}). The association between WBC (OR, 95% CI; 0.96, 0.90--1.02; *p* = 0.22) and neutrophil counts (OR, 95% CI; 0.93, 0.87--1.00; *p* = 0.058) and HE were no longer significant when using the definition of \>12.5 mL or 33% growth, whereas eosinophil count remained significantly associated with HE irrespective of the growth definition (OR, 6.92--31.60; all *p* \< 0.05).

###### 

Comparison of variable in the HE (\>6 mL or 33%) and non-HE groups after propensity score-matching.

  **Variable**                        **Non-HE (*n* = 216)**   **HE (*n* = 216)**   ***P-*value**
  ----------------------------------- ------------------------ -------------------- ---------------
  Age                                 60.8 ± 12.4              61.0 ± 12.6          0.896
  Male sex                            169 (78.2)               163 (75.5)           0.494
  Hypertension                        168 (77.8)               152 (70.4)           0.099
  Diabetes mellitus                   17 (7.9)                 23 (10.6)            0.319
  Current or previous smoking         75 (34.7)                65 (30.1)            0.304
  Current or previous drinking        71 (32.9)                66 (30.6)            0.605
  History of coronary heart disease   3 (1.4)                  2 (0.9)              1.000
  History of cerebral infarction      9 (4.2)                  6 (2.8)              0.43
  History of cerebral hemorrhage      12 (5.6)                 13 (6.0)             0.837
  Glasgow coma scale score            12 (9--14)               12 (8--14)           0.389
  International normalized ratio      1.00 (0.94--1.05)        0.99 (0.94--1.05)    0.584
  Glucose level, mmol/L               7.0 (6.0--8.4)           7.0 (6.0--8.2)       0.794
  Platelet count, 10^3^ cells/μL      187 (154--231)           201 (155--239)       0.09
  Time from onset to initial CT, h    2.5 (1.5--3.5)           2.5 (1.5--3.5)       0.477
  **Location of ICH**                                                               **0.092**
  Lobe                                21 (9.7)                 15 (6.9)             
  Deep                                192 (88.9)               191 (88.4)           
  Infratentorial                      3 (1.4)                  10 (4.6)             
  Baseline ICH volume, mL             21.6 (13.8--33.3)        24.1 (13.9--34.6)    0.653
  Intraventricular extension          82 (38.0)                88 (40.7)            0.555

*ICH, intracerebral hemorrhage; HE, hematoma expansion; CT, computed tomography*.

###### 

Comparison of variable in the HE (\>12.5 mL or 33%) and non-HE groups after propensity score-matching.

  **Variable**                        **Non-HE (*n* = 179)**   **HE (*n* = 179)**   ***P-*value**
  ----------------------------------- ------------------------ -------------------- ---------------
  Age                                 60.6 ± 12.3              60.6 ± 12.9          0.99
  Male sex                            144 (80.4)               137 (76.5)           0.368
  Hypertension                        141 (78.8)               128 (71.5)           0.112
  Diabetes mellitus                   13 (7.3)                 20 (11.2)            0.201
  Current or previous smoking         66 (36.9)                49 (27.4)            0.07
  Current or previous drinking        62 (34.6)                57 (31.8)            0.575
  History of coronary heart disease   4 (2.2)                  1 (0.6)              0.371
  History of cerebral infarction      7 (3.9)                  6 (3.4)              0.778
  History of cerebral hemorrhage      30 (3.4)                 15 (8.3)             0.398
  Glasgow coma scale score            13 (9--15)               12 (8--15)           0.327
  International normalized ratio      1.00 (0.95--1.05)        0.99 (0.94--1.05)    0.593
  Glucose level, mmol/L               7.0 (5.9--8.4)           6.9 (6.0--8.2)       0.908
  Platelet count, 10^3^ cells/μL      192 (158--233)           201 (149--239)       0.517
  Time from onset to initial CT, h    2.0 (1.5--3.0)           2.0 (1.5--3.5)       0.383
  **Location of ICH**                                                               **0.146**
  Lobe                                16 (8.9)                 11 (6.1)             
  Deep                                159 (88.8)               159 (88.8)           
  Infratentorial                      4 (2.2)                  9 (5.0)              
  Baseline ICH volume, mL             20.3 (13.1--32.1)        21.2 (12.6--30.6)    0.658
  Intraventricular extension          63 (35.2)                70 (39.1)            0.443

*ICH, intracerebral hemorrhage; HE, hematoma expansion; CT, computed tomography*.

###### 

Admission absolute and differential leukocyte counts before and after propensity score-matching.

                         **Original cohort**                  **Propensity score-matched cohort**                                                                                             
  ---------------------- ------------------------------------ ------------------------------------- ------------------- ------------------------------------ -------------------------------- -------------------
  **\>6 mL**             **Non-HE (*****n*** **=** **866)**   **HE (*****n*** **=** **200)**        ***P*****-value**   **Non-HE (*****n*** **=** **190)**   **HE (*****n*** **=** **190)**   ***P*****-value**
  WBC count              9,210 (7,178--12,040)                9,160 (6,530--11,188)                 0.061               9,445 (7,513--12,193)                9,160 (6,530--11,188)            0.035
  Neutrophil count       7,400 (4,845--10,300)                6,505 (4,100--9,088)                  0.001               7,500 (5,325--10,275)                6,505 (4,100--9,088)             0.003
  Monocyte count         455 (330--600)                       500 (400--625)                        0.02                500 (400--600)                       500 (400--625)                   0.306
  Lymphocyte count       1,200 (850--1,700)                   1,400 (925--2,023)                    0.001               1,200 (900--1,700)                   1,400 (925--2,023)               0.017
  Eosinophil count       30 (0--100)                          100 (10--160)                         \<0.001             25 (0--100)                          100 (10--160)                    0.001
  **\>12.5 mL**          **Non-HE (*****n*** **=** **950)**   **HE (*****n*** **=** **116)**        ***P*****-value**   **Non-HE (*****n*** **=** **116)**   **HE (*****n*** **=** **116)**   ***P*****-value**
  WBC count              9,190 (7,155--12,000)                9,220 (6,265--11,493)                 0.15                9,160 (7,468--11,165)                9,220 (6,265--11,493)            0.299
  Neutrophil count       7,240 (4,828--10,200)                6,330 (3,740--8,900)                  0.003               7,200 (5,300--9,825)                 6,330 (3,740--8,900)             0.028
  Monocyte count         460 (330--600)                       500 (400--700)                        0.006               425 (300--600)                       500 (400--700)                   0.011
  Lymphocyte count       1,200 (848--1,700)                   1,425 (1,015--2,275)                  \<0.001             1,200 (900--1,600)                   1,425 (1,015--2,275)             0.014
  Eosinophil count       30 (0--100)                          100 (10--198)                         \<0.001             100 (0--150)                         100 (10--198)                    0.003
  **\>33%**              **Non-HE (*****n*** **=** **892)**   **HE (*****n*** **=** **174)**        ***P*****-value**   **Non-HE (*****n*** **=** **163)**   **HE (*****n*** **=** **163)**   ***P*****-value**
  WBC count              9,305 (7,260--12,040)                8,715 (6,215--10,810)                 0.001               9,140 (7,200--11,570)                8,715 (6,215--10,810)            0.024
  Neutrophil count       7,400 (4,978--10,300)                5,655 (3,780--8,370)                  \<0.001             7,000 (5,000--9,600)                 5,655 (3,780--8,370)             0.001
  Monocyte count         460 (330--600)                       500 (388--630)                        0.023               480 (400--600)                       500 (388--630)                   0.176
  Lymphocyte count       1,200 (810--1,690)                   1,500 (1,068--2,200)                  \<0.001             1,300 (900--2,000)                   1,500 (1,068--2,200)             0.031
  Eosinophil count       20 (0--100)                          100 (18--200)                         \<0.001             10 (0--100)                          100 (18--200)                    0.003
  **\>6 mL or 33%**      **Non-HE (*****n*** **=** **841)**   **HE (*****n*** **=** **225)**        ***P*****-value**   **Non-HE (*****n*** **=** **216)**   **HE (*****n*** **=** **216)**   ***P*****-value**
  WBC count              9,300 (7,205--12,105)                8,820 (6,425--11,035)                 0.004               9,045 (7,185--11,685)                8,820 (6,425--11,035)            0.07
  Neutrophil count       7,400 (4,920--10,305)                6,100 (3,870--8,600)                  \<0.001             7,250 (5,000--9,900)                 6,100 (3,870--8,600)             0.003
  Monocyte count         460 (330--600)                       500 (385--620)                        0.031               420 (400--600)                       500 (385--620)                   0.109
  Lymphocyte count       1,200 (840--1,645)                   1,420 (975--2,100)                    \<0.001             1,200 (900--1,725)                   1,420 (975--2,100)               0.021
  Eosinophil count       30 (0--100)                          100 (15--165)                         \<0.001             85 (0--100)                          100 (15--165)                    0.001
  **\>12.5 mL or 33%**   **Non-HE (*****n*** **=** **884)**   **HE (*****n*** **=** **182)**        ***P*****-value**   **Non-HE (*****n*** **=** **179)**   **HE (*****n*** **=** **179)**   ***P*****-value**
  WBC count              9,300 (7,243--12,033)                8,725 (6,248--10,948)                 0.001               8,890 (7,142--10,985)                8,725 (6,248--10,948)            0.188
  Neutrophil count       7,400 (4,963--10,300)                5,800 (3,800--11,770)                 \<0.001             6,900 (4,775--8,875)                 5,800 (3,800--11,770)            0.013
  Monocyte count         460 (330--600)                       500 (380--630)                        0.026               500 (400--600)                       500 (380--630)                   0.075
  Lymphocyte count       1,200 (810--1,690)                   1,500 (1,000--2,193)                  \<0.001             1,200 (900--1,900)                   1,500 (1,000--2,193)             0.019
  Eosinophil count       20 (0--100)                          100 (10--193)                         \<0.001             30 (0--100)                          100 (10--193)                    0.001

*Data are presented as median (IQR) \[Unit: cells/μL\]. HE, hematoma expansion; IQR, interquartile range*.

###### 

Multivariate analyses of predicting hematoma expansion in the propensity score-matched cohorts.

                                **Adjusted[^**a**^](#TN4){ref-type="table-fn"} OR**   **95% CI**     ***P*-value**
  ----------------------------- ----------------------------------------------------- -------------- ---------------
  **\>6 mL growth**                                                                                  
  WBC count                     0.93                                                  0.87--0.98     0.021
  Neutrophil count              0.91                                                  0.86--0.97     0.006
  Monocyte count                1.48                                                  0.75--2.93     0.252
  Lymphocyte count              1.17                                                  0.92--1.48     0.192
  Eosinophil count              9.36                                                  1.46--59.68    0.018
  **\>12.5 mL growth**                                                                               
  WBC count                     0.98                                                  0.91--1.06     0.599
  Neutrophil count              0.95                                                  0.88--1.03     0.224
  Monocyte count                1.43                                                  1.04--1.97     0.024
  Lymphocyte count              1.34                                                  0.98--1.84     0.061
  Eosinophil count              14.50                                                 1.17--178.88   0.037
  **\>33% growth**                                                                                   
  WBC count                     0.93                                                  0.87--0.99     0.032
  Neutrophil count              0.91                                                  0.85--0.97     0.007
  Monocyte count                1.91                                                  0.82--4.42     0.131
  Lymphocyte count              1.17                                                  0.92--1.48     0.191
  Eosinophil count              11.04                                                 1.47--82.66    0.019
  **\>6 mL or 33% growth**                                                                           
  WBC count                     0.94                                                  0.89--0.99     0.04
  Neutrophil count              0.92                                                  0.87--0.98     0.009
  Monocyte count                1.87                                                  0.89--3.91     0.096
  Lymphocyte count              1.20                                                  0.97--1.50     0.09
  Eosinophil count              6.92                                                  1.20--39.78    0.03
  **\>12.5 mL or 33% growth**                                                                        
  WBC count                     0.96                                                  0.90--1.02     0.22
  Neutrophil count              0.93                                                  0.87--1.00     0.058
  Monocyte count                2.03                                                  0.87--4.71     0.1
  Lymphocyte count              1.20                                                  0.94--1.52     0.138
  Eosinophil count              31.60                                                 3.23--308.70   0.003

*OR for 10^3^ cells increase*.

*Adjusted for history of cerebral hemorrhage, glasgow coma scale score, time to initial computed tomography, and baseline hematoma volume. WBC, white blood cell; OR, odds ratio; CI, confidence interval*.

The receiver operating characteristic (ROC) analyses demonstrated that eosinophil count had the best discrimination ability for HE irrespective of growth definition, with the highest area under the ROC curve (AUC) of 0.640 (95% CI, 0.595--0.685; *p* \< 0.001; [Table 8](#T8){ref-type="table"}) at the definition of \>33% growth; the best predictive cut-off value was 45 cells/μL (sensitivity 69.5%, specificity 58.9%). Additionally, when using the same definition, the predicted model incorporating eosinophil count, baseline hematoma volume (BV), and time from symptom onset to initial CT (TST) achieved a 8.9% improvement in the AUC (AUC = 0.675; 95% CI, 0.635--0.715; *p* \< 0.001; [Figure 1](#F1){ref-type="fig"}) over a model based on BV and TST alone (AUC = 0.620; 95% CI, 0.575--0.665; *p* \< 0.001). The highest AUC of the combined models was 0.731 (95% CI, 0.686--0.778; *p* \< 0.001; sensitivity 85.3%, specificity 51.1%; [Table 9](#T9){ref-type="table"}), obtained when using the HE definition of \>12.5 mL expansion.

![Receiver operating characteristic curves by using a growth definition of \>33%, with a binary logistic regression model incorporating BV, TST, and EC (AUC = 0.675) or BV and TTS only (AUC = 0.620). BV, baseline hematoma volume; TST, time from symptom onset to initial computed tomography; EC, eosinophil count; AUC, area under the receiver operating characteristic curve.](fneur-10-01164-g0001){#F1}

###### 

Comparison of AUCs of leukocyte counts in predicting HE by different growth definitions.

                     **\>6 mL**             **\>12.5 mL**          **\>33%**              **\>6 mL or \>33%**    **\>12.5 mL or \>33%**
  ------------------ ---------------------- ---------------------- ---------------------- ---------------------- ------------------------
  WBC count          0.542 (0.498--0.587)   0.541 (0.483--0.599)   0.583 (0.536--0.631)   0.563 (0.520--0.606)   0.575 (0.528--0.622)
  *P-*value          0.061                  0.15                   0.001                  0.004                  0.001
  Neutrophil count   0.572 (0.528--0.617)   0.584 (0.526--0.642)   0.625 (0.579--0.672)   0.599 (0.557--0.641)   0.616 (0.570--0.662)
  *P-*value          0.001                  0.003                  \<0.001                \<0.001                \<0.001
  Monocyte count     0.553 (0.508--0.587)   0.578 (0.523--0.634)   0.554 (0.508--0.601)   0.547 (0.504--0.590)   0.552 (0.506--0.598)
  *P-*value          0.02                   0.006                  0.024                  0.031                  0.027
  Eosinophil count   0.591 (0.547--0.636)   0.634 (0.581--0.687)   0.640 (0.595--0.685)   0.604 (0.562--0.647)   0.631 (0.586--0.675)
  *P-*value          \<0.001                \<0.001                \<0.001                \<0.001                \<0.001

*AUC, area under the receiver operating characteristic curve; HE, hematoma expansion; WBC, white blood cell*.

###### 

AUCs in the 2 combined predicted models using various growth definitions of HE.

                       **AUC (TST+BT)**       ***P-*value**   **AUC (TST+BT+EC)**    ***P-*value**   **Improvement**
  -------------------- ---------------------- --------------- ---------------------- --------------- -----------------
  \>6 mL               0.710 (0.672--0.747)   \<0.001         0.724 (0.688--0.759)   \<0.001         2.0%
  \>12.5 mL            0.710 (0.662--0.758)   \<0.001         0.731 (0.686--0.778)   \<0.001         3.0%
  \>33%                0.620 (0.575--0.665)   \<0.001         0.675 (0.635--0.715)   \<0.001         8.9%
  \>6 mL or \>33%      0.668 (0.629--0.707)   \<0.001         0.690 (0.653--0.727)   \<0.001         3.3%
  \>12.5 mL or \>33%   0.642 (0.601--0.684)   \<0.001         0.679 (0.639--0.720)   \<0.001         5.8%

*AUC, area under the receiver operating characteristic curve; HE, hematoma expansion; TST, time from symptom onset to initial CT; BV, baseline ICH volume; EC, eosinophil count*.

Discussion {#s4}
==========

Our study revealed that peripheral counts of WBC, neutrophil, and monocyte on admission were independently associated with the risk of early hematoma enlargement. However, these associations could be affected by HE definitions. Intriguingly, we found a robustly correlation between eosinophil count and increased risk of HE. Furthermore, as compared with other leukocyte types, eosinophil count had the best discrimination ability for HE irrespective of growth definition.

There is no universally agreed definition for HE. A predicted model used an absolute growth definition of 6 mL increase to determine the risk factors associated with HE ([@B19]). The relative growth definition of \>33% was used by many studies ([@B3], [@B5], [@B21]), since it could improve the detection rate of HE for ICH that presented with a small volume upon admission. In another prediction model, HE was defined as the combination of 6 mL and 33% increase ([@B18]), which was also widely applied in recent investigations ([@B22]--[@B24]). When using the absolute growth of \>12.5 mL, the HE rate we observed was the lowest, consisting with the previous publication ([@B4]). In addition to using the growth definition with a specific cut-point, any degree of growth was adopted to define HE as well ([@B17]). One drawback was that the observation of HE would be susceptible to measurement errors, especially in patient with a similar follow-up and baseline ICH size. Hence, we did not analyze this definition in our study.

The present study systematically delineated the relationship of leukocyte counts with the most commonly used definitions of HE. Our findings were generally in accordance with the published literature ([@B8]), suggesting that the risk of HE is inversely associated with WBC and neutrophil count and directly associated with monocyte count. Interpreting the divergent effect of differential leukocyte counts on the hematoma progression needs to stand on the pathophysiological perspectives. A pronounced inflammation occurs rapidly once the intracranial hematoma is formed, inducing perihematomal leukocytes infiltration within hours ([@B6], [@B11]). In addition to acting on the components within hematoma, exudative leukocytes can interact with platelets and coagulation factors, and promote thrombus formation through shifting the clotting balance ([@B25]--[@B27]). A procoagulant state caused by the acute inflammation may limit further hematoma enlargement. Neutrophils and monocytes are predominant WBCs, and both enter the brain from the blood-brain barrier after ICH ([@B6], [@B9]). Beyond the bactericidal actions known in the immune response, they have been found to play roles in coagulation pathway. Activated neutrophils can release tissue factor (TF) and downregulate the TF pathway inhibitor in favor of thrombus formation ([@B28], [@B29]). Through interacting with platelets, factor X and XII, neutrophils can enhance thrombin generation and stabilize fibrin ([@B29], [@B30]). On the contrary, the membrane surface of monocyte is shown to be rich in anticoagulant factors such as TF pathway inhibitor, endothelial protein C receptor, and thrombomodulin ([@B26], [@B31], [@B32]), which may physiologically inhibit thrombus formation and promote fibrinolysis. These preclinical data on the relationship of leukocytes with coagulation components improve the biological rationality of our results.

In clinical studies, the relevance of leukocyte counts to ICH prognosis has attracted mounting attention. Some suggested that admission WBC count was irrelevant to adverse ICH prognosis ([@B13]--[@B15], [@B17]). Two multicenter studies reported that higher monocyte count at admission was independently associated with 30-day case fatality, whereas neutrophil and total WBC count were not ([@B15], [@B17]). The researchers conjectured that HE may be the link between monocyte count and poor ICH outcome, and this hypothesis was confirmed by our results. Besides, investigators from the INTERACT2 found no association between elevated WBC count and disability or death at 3 months in patients with acute ICH, after adjusting for baseline clinical and imaging confounders ([@B13]). In our study, admission WBC count was inversely associated with the risk of HE, indicating a beneficial role of the acute inflammation in limiting HE, and providing indirect evidence for previous literatures.

Eosinophil is a multifunctional leukocyte that involves in the pathogenesis of diverse inflammatory processes ([@B33]), but its specific role in ICH has not yet been elucidated. The mechanism explaining the association of eosinophil count with augmented risk of HE is unclear. Due to the quantitative correlation with total WBC count, one could speculate that our results may only reflect an indirect connection, rather than a causality. Nevertheless, eosinophil count may be a useful biomarker to predict HE. In our study, eosinophil count was robustly correlated with HE irrespective of growth definition, and had the best discrimination ability as compared with other leukocyte types. Baseline ICH volume and onset-to-scan time are strong predictors of HE ([@B2], [@B34]), and are two commonly used variables in the currently available models ([@B18]--[@B20]). Our results remained significant after adjusting for the two risk factors in the multivariable analyses. Besides, our findings suggest that routine clinical model incorporating eosinophil count could improve the discrimination ability for HE, which might help select more patients with acute ICH for hemostasis treatment in clinical trials.

We did not find an association of HE with WBC and neutrophil count when using the absolute definition of 12.5 mL growth or the combined definition of 12.5 mL with 33% growth. In contrast, a positive association between monocyte count and ICH expansion risk was observed under the definition of \>12.5 mL growth only. Although the mechanisms underlying our observations are poorly understood, our findings provide a reasonable explanation for the inconsistent role of monocytes in HE ([@B8], [@B17]). Additionally, studies aimed at identifying risk factors of HE could be based on multiple growth definitions, which may be conducive to capture a comprehensive result. As the divergent effect of neutrophils and monocytes on hematoma progression, future therapeutic strategies should lay particular emphasis on precise regulation of the immune response instead of an extensive anti-inflammatory treatment. Given the intimate relationship between eosinophil count and expansion risk, the role of this leukocyte subtype in the pathophysiology of ICH also merits close attention in basic research. Once the underlying mechanisms are uncovered, this inflammatory marker may provide a novel target for anti-expansion treatment in patients with acute ICH.

This study has several limitations. First, our results are based on a single-center, retrospective analysis. Second, patients who received anticoagulant or antiplatelet treatment before ICH are exclude from this study, thus our results may not apply to these populations. In addition, we perform correlation analyses only upon the most commonly used HE definitions, which may also limit the universality of our results. Third, inflammatory marker such as C-reactive protein, is a predictor of HE ([@B35]). We are not able to control for this confounder in our analyses due to lack of emergency laboratory data. Future research needs to clarify whether C-reactive protein has an impact on the relationship between leukocyte counts and HE. Finally, pre-hospital treatment or some specific conditions diagnosed insufficiently might have affected leukocyte counts, although we eliminate them to the best knowledge.

Conclusions {#s5}
===========

Among patients with acute spontaneous ICH, admission counts of WBC, neutrophil, and monocyte are independently associated with the risk of HE. However, using different HE definition affects the stability of theses associations. Eosinophil count robustly predicts HE regardless of the growth definition. This laboratory parameter is widely-accessible, and may be a useful biomarker for the risk stratification of early hematoma enlargement in emergency work.
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